You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

logo

Product menu

Your trusted reliever Your trusted reliever

              Our content

              Our content

The Birth of Breakthrough

The Birth of a Breakthrough

Embark on a journey back to the 1960s, where David Jack and Roy Brittain, their groundbreaking work paved the way for Ventolin, the world's first selective 32-receptor agonist1

Read More

Fast Companion

Fast Companion

Ventolin is the trusted reliever option with fast onset of action1,2

Read More

Proven Safety

Proven Safety

Meta-analysis of data from 24 trials over the past 25 years shows that when used SABA appropriately for symptom relief, SABA does not contribute to excess rates of mortality.4

Read More

Guiding Asthma Control

Guiding Asthma Control

Monitoring SABA use is valuable in assessing asthma1-3

Read More

Longstanding Legacy

Longstanding Legacy

Ventolin long standing legacy, rooted in years of dependable efficacy and trust, affirms its role in the tapestry of asthma management.1

Read More

       THE BIRTH OF A BREAKTHROUGH

 Trusted Reliever's Journey: How It Began?

David Jack

Embark on a journey back to the 1960s, where David Jack and Roy Brittain, fueled by a vision for better asthma care, changed the course of treatment forever1

Their groundbreaking work paved the way for Ventolin, the world's first selective β2-receptor agonist.1
 

Watch our Ventolin standards and manufacturing video now!

Trusted Reliver

             

Challenge

Challenge

Overcoming isoprenaline cardiac side effects with a selective and safer bronchodilator.1

Breakthrough

Breakthrough

Discovery of salbutamol as the first selective beta2-agonist for airway diseases-related bronchospasm.1

Legacy

Legacy

Salbutamol, known as Ventolin, remains a trusted reliever for asthma management.1

Want to know more?

 

Discover More

Learn how Ventolin continues to impact asthma care today by visiting our 'Longstanding Legacy' section.



 

 

Question for your

How significant do you believe the invention of Ventolin was in the evolution of asthma treatment?

A-Extremely significant
B-Very significant
C-Somewhat significant
 

References:

References:

1. Page C, et al. Br J Clin Pharmacol. 2013;75(5):1213-1218.

2. GINA. Global strategy for asthma management and prevention. 2023.

3. GSK. Salbutamol (inhaled formulations) Global Datasheet: v26, April 2019.

4. Sriprasart T;Adv Ther;2023;40;133–158

         FAST COMPANION

line
Fast Companion Rapid Relief

Your Fast Companion: How Does 50 Years of Rapid Relief Change Lives?

Ventolin is the trusted reliever option with fast onset of action1,2

Faster Onset

Fast Onset of Action

* Bronchodilator (FEV1) was consistently higher with salbutamol by approximately 100 mL as compared to BUD/FORM at 2 min.3



• This trend continued for the full 30 minutes.3

 

Consistent Improvement

Consistent Improvement

• Salbutamol consistently and significantly improved FEV, compared to BUD/FORM.3

 

 

 

References:

References:

1. Price AH, et al. Drugs. 1989;38(1):77-122.

2. Ventolin Prescribing information

3. Kearns N, et al. Thorax. 2022 Jul 18:thoraxjnl-2022-219052.

         PROVEN SAFETY

line

What is Behind 50 Years of Proven
Safety?

Meta-analysis of data from 24 trials over the past 25 years shows that when used SABA appropriately for symptom relief, SABA does not contribute to excess rates of mortality.1

proven safety meta analysis
used saba appropriately for symptom

When used SABA appropriately for symptom relief, SABA Does NOT contribute to excess rates of mortality.1

No rcts have linked asthma

No RCTs have linked asthma mortality associated with SABA use.1


 

SAE Risk

SAE risk was comparable between SABA and ICS treatments (incidence: 0-5% for both treatments)1


3.9% of patient using saba

Only 3.9% of patient using as-needed SABA reliever therapy discontinued due to adverse events.1


References:

References:

1. Sriprasart T, et al. Adv Ther. 2023;40(1):133-158.

        GUIDING ASTHMA CONTROL

line

How Does Ventolin Guide Asthma Control?

Monitoring SABA use is valuable in assessing asthma.1-3

gina recommended indicator

 

GINA-Recommended Indicators for

Assessment of Asthma Control:3

• *†Using SABA inhaler more than twice a week"


• *†Experiencing daytime symptoms more than twice a week


• *†Waking up with night-time symptoms"


• *†Experiencing activity limitations

*Other important criteria include: daytime symptoms more than twice/week; any night waking due to asthma; any activity limitation due to asthma.
†Within the last four weeks.

SABAs should not be the only or main treatment in patients with asthma.3
SABAs should be used appropriately with regular ICS-containing therapies as prescribed; on-demand use of SABA should not exceed 4 times daily as this may indicate deteriorating asthma control.4

References:

References:

1. Amirav I, et al. Adv Ther. 2023;40(7):2927-2943.

2. Domingo C, et al. Adv Ther. 2023;40(4):1301-1316.

3. GINA. Global strategy for asthma management and prevention. 2023.

4. GSK. Salbutamol (inhaled formulations) Global Datasheet: v26, April 2019.

        LONGSTANDING LEGACY

line

 

Ready to Uncover Your Trusted Reliever's
50-Year Legacy?

Ventolin's long standing legacy, rooted in years of dependable efficacy and trust, affirms its role in the tapestry of asthma management.

Longstanding legacy
decade of legacy

 

Decades of Legacy

SABAs have been a mainstay of asthma treatment since the 1950s, and have been mainly recommended as-needed for symptom relief alongside daily ICS-based maintenance treatment for the past 30 years.1
 


 

fast onset

 

Fast Onset of Action

Ventolin (salbutamol sulfate) inhalers deliver fast onset of action within 5 minutes and peak bronchodilation within 10 minutes.2

 


 

 

 

 

 

sustained trust

 

Sustained Trust

Nebulised Ventolin remains an effective treatment for relieving acute bronchospasm associated with AEA within a few minutes.2

 

 

 

 

 

 

 

proven safety

 

Proven Safety

No Evidence of Causal Link Between SABA Use as a Reliever and Mortality or Adverse Events.3

 

 

 

 

 

 

 

 

continued endorsement

 

Continued Endorsement

SABAs are recommended by the GINA report and BTS/SIGN, GEMA and
NHLBI guidance as first-line treatment for AEA.4,5




 

 

References:

1. Domingo C, et al.Adv Ther. 2023;40(4):1301-1316.

2. Ventolin Prescribing Information.

3. Amirav I, et al. Adv Ther. 2023;40(7):2927-2943.

4. NHLBI. 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. 2020.

5. GINA. Global strategy for asthma management and prevention. 2023.

Hear more about Your Trusted Reliver from Prof. Gabriel García, Director of the Respiratory Research Center, CEPIR, La Plata, Argentina

line
role of saba in the management of asthma
cost effective to use saba
combination reliever or only saba

Ventolin safety information1

  • Contraindications:

    Hypersensitivity to the active substance or any of the excipients.

    Non-i.v. formulations of salbutamol must not be used to arrest uncomplicated premature labour or threatened abortion.

  • Undesirable effects

    Common: Tremor, headache and Tachycardia

Abbreviations:

AEA: Acute exacerbation of asthma, SABA: Short-Acting Beta Agonists, ICS: Inhaled Corticosteroids, ACT: Asthma Control Test, SAE: Serious Adverse Events, RCT: Randomized Clinical Trial

GSK does not recommend, endorse, or accept liability for the site.

For more information, please refer to the prescribing information or contact GlaxoSmithKline via gcc.medinfo@gsk.com
To report Adverse Event/s associated with the use of GSK product/s, please contact us via
gulf.safety@gsk.com
To report quality complaint/s associated with the use of GSK product/s, please contact us via
 Gulf.ProductQualityComplaints@gsk.com

Department of Pharmacovigilance & Drug Information
Drug Safety Center
Ministry of Health, Sultanate of Oman
Phone Nos. 0096822357687 / 0096822357690
Fax: 0096822358489
Email: pharma-vigil@moh.gov.om
Website: www.moh.gov.om

 دائرة التيقظ و المعلومات الدوائية
مركز سلامة الدواء
وزارة الصحة, سلطنة عمان
هاتف: 0096822357687 / 0096822357690
0096822358489 :فاكس
pharma-vigil@moh.gov.om :البريد االكتروني
www.moh.gov.om : الموقع االكتروني

Trademarks are owned by or licensed to the GSK group of companies 
©2025 GSK group of companies or its licensor. All rights reserved.

PM-RCH-SLB-WCNT-240003 | Date of Preparation February 2025